Patents Assigned to Genentech
  • METHODS FOR VIRAL INACTIVATION AND OTHER ADVENTITIOUS AGENTS
    Publication number: 20230159886
    Abstract: The invention provides for methods of viral inactivation using high temperature short time (HTST) treatment and adjustment of various parameters such that generation of precipitate and depositions of precipitate are reduced and/or minimized.
    Type: Application
    Filed: September 27, 2022
    Publication date: May 25, 2023
    Applicant: Genentech, Inc.
    Inventors: Masaru Ken SHIRATORI, Robert David KISS, Hardayal PRASHAD, Raquel IVERSON, Justin BOURRET, Michael KIM, Salim CHARANIYA
  • CELL-BASED METHODS FOR PREDICTING POLYPEPTIDE IMMUNOGENICITY
    Publication number: 20230160907
    Abstract: The presently disclosed subject matter provides methods for determining the propensity of a polypeptide or a fragment thereof, e.g., an antibody or a fragment thereof, to elicit production of anti-drug antibodies (ADAs) and kits for performing such methods.
    Type: Application
    Filed: January 11, 2023
    Publication date: May 25, 2023
    Applicant: GENENTECH, INC.
    Inventors: Lynn Anne Kamen, Rachel Ann Melendez, Shan Chung
  • Treatment of metastatic breast cancer
    Patent number: 11655305
    Abstract: The present invention concerns treatment of previously untreated HER2-positive metastatic breast cancer with a combination of a growth inhibitory HER2 antibody, a HER2 dimerization inhibitor antibody and a taxane. In particular, the invention concerns the treatment of HER2-positive metastatic breast cancer in patients who did not receive prior chemotherapy or biologic therapy with a HER2 antibody binding essentially to epitope 2C4, a HER2 antibody binding essentially to epitope 4D5, and a taxane. The invention further comprises extending survival of such patients by the combination therapy of the present invention. In a preferred embodiment, the treatment involves administration of trastuzumab, pertuzumab and docetaxel.
    Type: Grant
    Filed: June 2, 2020
    Date of Patent: May 23, 2023
    Assignee: Genentech, Inc.
    Inventors: Virginia Paton, Anne Blackwood Chirchir, Pam Klein
  • Oxadiazole transient receptor potential channel inhibitors
    Patent number: 11655245
    Abstract: The invention relates to methods of using compounds formula I: and pharmaceutically acceptable salts thereof wherein A, X, R1, R4 and n are as defined herein. In addition, the present invention relates to methods of manufacturing and methods of using the compounds of formula I as well as pharmaceutical compositions containing such compounds. The compounds may be useful in treating diseases and conditions mediated by TRPA1, such as pain.
    Type: Grant
    Filed: June 16, 2020
    Date of Patent: May 23, 2023
    Assignee: Genentech, Inc.
    Inventors: Jack Alexander Terrett, Huifen Chen, Lea Constantineau-Forget, Robin Larouche-Gauthier, Luce Lépissier, Francis Beaumier, Martin Déry, Chantal Grand-Maître, Claudio Sturino, Matthew Volgraf, Elisia Villemure
  • Subcutaneous HER2 antibody formulations
    Patent number: 11654105
    Abstract: Fixed dose HER2 antibody formulations for subcutaneous administration are provided along with their use in the treatment of cancer. The formulations include fixed dose subcutaneous formulations of pertuzumab and subcutaneous co-formulations of pertuzumab and trastuzumab, and their use in the treatment of cancer.
    Type: Grant
    Filed: August 22, 2022
    Date of Patent: May 23, 2023
    Assignees: Genentech, Inc., Hoffmann-La Roche
    Inventors: Jennifer Eng-Wong, Whitney Kirschbrown, Tarik Ali Khan, Jasper Lin, Sreedhara Alavattam, Amit Garg, Sarah Heeson, Tanja Badovinac-Crnjevic, Christine Wurth
  • STROMAL GENE SIGNATURES FOR DIAGNOSIS AND USE IN IMMUNOTHERAPY
    Publication number: 20230151103
    Abstract: The invention provides methods for identifying an individuals with a disease or disorder who is less likely to respond to immunotherapy alone, the method comprising determining the presence of a stromal gene signature in a sample from the individual, said signature comprising one or more of FAP, FN1, MMP2, PDGFRB, or THY, wherein an increase in the level of expression of the one or more genes in the stroma gene signature relative to a median level identifies an individual for treatment with an immunotherapy and with a suppressive stromal antagonist. In some aspects, the invention provides methods for treating an individual displaying the stromal gene signature. In other aspects, the invention provides kits for determining the presence of a stroma gene signature in a sample from an individual.
    Type: Application
    Filed: August 12, 2022
    Publication date: May 18, 2023
    Applicant: Genentech, Inc.
    Inventors: Priti HEGDE, Luciana MOLINERO, Sanjeev MARIATHASAN, Shannon TURLEY, Jillian ASTARITA, Rafael CUBAS, Yagai YANG
  • METHODS OF TREATING RELAPSING MULTIPLE SCLEROSIS USING AN INHIBITOR OF BRUTON'S TYROSINE KINASE
    Publication number: 20230149395
    Abstract: Provided herein are methods of treating Relapsing Multiple Sclerosis (RMS) in a subject in need thereof, by administering to the subject about 200 mg of fenebrutinib twice daily, or an equivalent amount of a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: April 1, 2021
    Publication date: May 18, 2023
    Applicants: Genentech, Inc., Hoffmann-La Roche Inc.
    Inventors: Hideki GARREN, Edmond Huatung TENG, Aurelien VIACCOZ, Hans-Christian VON BUEDINGEN
  • PREDICTING TOLERABILITY IN AGGRESSIVE NON-HODGKIN LYMPHOMA
    Publication number: 20230154626
    Abstract: Systems and methods described herein improve outcomes of subjects with lymphoma. Subjects with lymphoma may be able to avoid conventional treatments that have a high probability of leading to an adverse effect in the subject. Systems and methods allow for a more accurate prediction of subjects who cannot tolerate a particular treatment. Methods may include accessing an input data set that includes multiple input data values pertaining to a particular subject with lymphoma. The method may further include inputting the input data set into a machine-learning model to generate a score corresponding to the degree to which the particular subject will tolerate a particular treatment. The method may include outputting a prediction of the tolerance of the particular subject to the particular treatment using the generated score.
    Type: Application
    Filed: January 19, 2023
    Publication date: May 18, 2023
    Applicants: GENENTECH, INC., HOFFMANN-LA ROCHE INC.
    Inventors: Tina Geritz Nielsen, Joseph Nathaniel Paulson, Daniel Jay Schneider, Edward Jean Bataillard, Carl Wilson Harris, III, Carsten Henneges, Yoonha Choi
  • Silvestrol antibody-drug conjugates and methods of use
    Patent number: 11648315
    Abstract: The invention relates generally to a silvestrol molecule activated with a leaving group. The invention further relates generally to an antibody-drug conjugate comprising an antibody conjugated by a linker to one or more silvestrol drug moieties and methods of treatment.
    Type: Grant
    Filed: March 23, 2020
    Date of Patent: May 16, 2023
    Assignee: Genentech, Inc.
    Inventors: Thomas Pillow, Andrew G. Polson, Bing Zheng
  • Stable anti-CD79B immunoconjugate formulations
    Patent number: 11648317
    Abstract: The disclosure provides stable pharmaceutical compositions comprising an anti-CD79b immunoconjugate and a surfactant. The disclosure also provides methods for using such compositions for the treatment of cancer.
    Type: Grant
    Filed: April 12, 2019
    Date of Patent: May 16, 2023
    Assignee: Genentech, Inc.
    Inventors: Ankit R. Patel, Jun Liu
  • Pyrazolochlorophenyl compounds, compositions and methods of use thereof
    Patent number: 11649241
    Abstract: Compounds of Formula I and methods of use as Janus kinase inhibitors are described herein.
    Type: Grant
    Filed: February 12, 2021
    Date of Patent: May 16, 2023
    Assignee: Genentech, Inc.
    Inventors: Mark Zak, F. Anthony Romero, Po-wai Yuen, Emily J. Hanan
  • APOPTOSIS INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES
    Publication number: 20230143532
    Abstract: Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-2 protein.
    Type: Application
    Filed: October 7, 2022
    Publication date: May 11, 2023
    Applicants: AbbVie Inc., Genentech, Inc., The Walter and Eliza Hall Institute of Medical Research
    Inventors: Milan Bruncko, Hong Ding, George A. Doherty, Steven W. Elmore, Lisa A. Hasvold, Laura Hexamer, Aaron R. Kunzer, Xiaohong Song, Andrew J. Souers, Gerard M. Sullivan, Zhi-Fu Tao, Gary T. Wang, Le Wang, Xilu Wang, Michael D. Wendt, Robert Mantei, Todd M. Hansen
  • Process for the preparation of tricyclic PI3K inhibitor compounds and methods for using the same for the treatment of cancer
    Patent number: 11643421
    Abstract: The present disclosure provides for methods for preparing tricyclic PI3K inhibitor compounds in high yield and purity in aqueous solvent systems.
    Type: Grant
    Filed: December 8, 2020
    Date of Patent: May 9, 2023
    Assignee: GENENTECH, INC.
    Inventors: Andreas Stumpf, Remy Angelaud, Andrew McClory, Herbert Yajima, Chudi Ndubaku, Alan Olivero
  • Uses of Tau Phosphosites as Biomarkers for Alzheimer's Disease
    Publication number: 20230132508
    Abstract: The present disclosure relates to methods of measuring and analyzing phosphorylation sites in the tau protein and determining correlations with other biomarkers of Alzheimer's disease and tauopathies.
    Type: Application
    Filed: March 31, 2021
    Publication date: May 4, 2023
    Applicants: Genentech Inc., Washington University
    Inventors: Kristin Ruth Wildsmith, Balazs Toth, Randall Bateman, Nicolas Barthelemy
  • Adjuvant treatment of HER2-positive breast cancer
    Patent number: 11638756
    Abstract: Methods are provided for the adjuvant treatment of operable HER2-positive primary breast cancer in human patients by administration of pertuzumab in addition to chemotherapy and trastuzumab. The methods reduce the risk of recurrence of invasive breast cancer or death for a patient diagnosed with HER2-positive early breast cancer (eBC) compared to administration of trastuzumab and chemotherapy, without pertuzumab.
    Type: Grant
    Filed: August 22, 2022
    Date of Patent: May 2, 2023
    Assignees: Genentech, Inc., Hoffman-La Roche Inc.
    Inventors: Mark C. Benyunes, Graham Alexander Ross
  • Prevention of disulfide bond reduction during recombinant production of polypeptides
    Patent number: 11639395
    Abstract: The invention concerns methods for preventing the reduction of disulfide bonds during the recombinant production of disulfide-containing polypeptides. In particular, the invention concerns the prevention of disulfide bond reduction during harvesting of disulfide-containing polypeptides, including antibodies, from recombinant host cell cultures.
    Type: Grant
    Filed: November 2, 2020
    Date of Patent: May 2, 2023
    Assignee: Genentech, Inc.
    Inventors: Yung-Hsiang Kao, Michael W. Laird, Melody Trexler Schmidt, Rita L. Wong, Daniel P. Hewitt
  • BIOMARKERS FOR PREDICTING RESPONSE TO IL-6 ANTAGONIST IN COVID-19 PNEUMONIA
    Publication number: 20230125415
    Abstract: A method of treating pneumonia in a patient is disclosed comprising administering an effective amount of an IL-6 antagonist to a patient identified as having elevated ferritin level. Also disclosed is a method of achieving an improved clinical response in a patient with pneumonia comprising: a. measuring ferritin level in the patient, and b. administering an effective amount of an IL-6 antagonist to the patient identified as having an elevated ferritin level. The improved clinical response achieved includes: no death by Day 28, not mechanically ventilated by Day 28 (wherein the patient was not mechanically ventilated at baseline), better ordinal score at Day 28, and/or reduced time to hospital discharge within 28 days, compared to the clinical response in a patient with pneumonia and ferritin level that is not elevated.
    Type: Application
    Filed: March 19, 2021
    Publication date: April 27, 2023
    Applicant: Genentech, Inc.
    Inventors: Min Bao, Fang Cai, Jennifer Tom, Larry Wilse Tsai
  • Cysteine Engineered Antibodies and Conjugates
    Publication number: 20230130874
    Abstract: Cysteine engineered antibodies comprising a free cysteine amino acid in the heavy chain or light chain are prepared by mutagenizing a nucleic acid sequence of a parent antibody and replacing one or more amino acid residues by cysteine to encode the cysteine engineered antibody; expressing the cysteine engineered antibody; and isolating the cysteine engineered antibody.
    Type: Application
    Filed: May 13, 2022
    Publication date: April 27, 2023
    Applicant: Genentech, Inc.
    Inventors: Sunil Bhakta, Hans Erickson, Jagath R. Junutula, Katherine Kozak, Rachana Ohri, Thomas Harden Pillow
  • Versatile syringe platform
    Patent number: 11633545
    Abstract: Apparatus and methods for medicament delivery. The apparatus may include, and the methods may involve, a delivery device for delivering a target amount of the medicament from a distal end of the device. The device may include a rod for moving a plunger that discharges the medicament from the distal end. The device may avoid or reduce deformation of the plunger during the discharge. The plunger motion may be stopped by detent that interacts with the rod. The apparatus and the methods may provide an operator indication of progress of stages of operation. The device may feature triggers corresponding to stages of medicament displacement from the device, such as pre-delivery stages, including priming.
    Type: Grant
    Filed: July 17, 2020
    Date of Patent: April 25, 2023
    Assignee: Genentech, Inc.
    Inventors: Lionel Vedrine, Steven N. Roe, Mukund Patel
  • Randomized configuration targeted integration of nucleic acids
    Patent number: 11634836
    Abstract: The presently disclosed subject matter relates to “Randomized Configuration Targeted Integration” (also referred to herein as “Randomized Chain Targeted Integration”) (RCTI) strategies for the generation and identification of host cells capable of expressing recombinant proteins, e.g., monoclonal antibodies, as well as compositions derived from the same, e.g., bispecific antibodies, and other complex format proteins, e.g., membrane protein complexes and other difficult to express molecules.
    Type: Grant
    Filed: December 27, 2021
    Date of Patent: April 25, 2023
    Assignee: Genentech, Inc.
    Inventors: Shahram Misaghi, Bradley R. Snedecor